Oral magnesium and outcomes in US veterans with heart failure
Yin Y, Costello RB, Fonarow GC, Heidenreich PA, Morgan CJ, Faselis C, Cheng Y, Zullo AR, Liu S, Lam PH, Rosanoff A, Vargas JD, Gottlieb SS, Deedwania P, Moore HJ, Shao Y, Sheriff HM, Wu WC, Zeng-Treitler Q, Ahmed A
European heart journal · 5 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Office of Dietary Supplements
- Gobierno
- Department of Veterans' Affairs, Australian Government
- Universidad u hospital
- Norges Idrettshøgskole
- Gobierno
- National Institutes of Health
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- NIH
- Gobierno
- US Government
- Gobierno
- VA
- Gobierno
- VA Information Resource Center
- Gobierno
- HSRD VA
- Gobierno
- NHLBI
- Gobierno
- NIH HHS
- Gobierno
- VA/CMS
- Gobierno
- NHLBI NIH HHS
- Gobierno
- NIH Office of Dietary Supplements
- Gobierno
- Department of Veterans Affairs
- Subvenciones
- Office of Dietary Supplements (5R01HL156518)
Según 16 financiadores declarados.
Publicación
- Publicado
- 2025-10-14 · Eur Heart J · vol. 47 · número 1 · págs. 80–90
- Editorial
- Oxford University Press
- Citado
- 6 citas · más que el 92% de estudios similares · 3.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Magnesium in Health and Disease · Potassium and Related Disorders · Heart Failure Treatment and Management
- Palabras clave
- Heart failure, Magnesium, Clinical trial, Risk factor, MEDLINE
- MeSH
- humans, magnesium deficiency, magnesium, treatment outcome, hospitalization, administration, oral, aged, middle aged, veterans, united states, female, male, heart failure
20 autores
- Ying Yin🇺🇸 · autor de correspondenciaGeorge Washington University; Veterans Health Administration
- Rebecca B. Costello🇺🇸National Institutes of Health; Office of Dietary Supplements
- Gregg C. Fonarow🇺🇸University of California, Los Angeles
- Paul A. Heidenreich🇺🇸Veterans Health Administration; Palo Alto Veterans Institute for Research; Stanford University
- Charity Johanna Morgan🇺🇸Veterans Health Administration; University of Alabama at Birmingham
- Charles J. Faselis🇺🇸Uniformed Services University of the Health Sciences; George Washington University; Veterans Health Administration
- Yan Cheng🇺🇸George Washington University; Veterans Health Administration
- Andrew R. Zullo🇺🇸Brown University; Providence VA Medical Center
- Simin Liu🇺🇸University of California, Irvine
- Phillip Hong Lam🇺🇸MedStar Washington Hospital Center; Georgetown University
- Aaron J. Rosanoff🇺🇸Center Point
- Jose D Vargas🇺🇸Georgetown University; Veterans Health Administration
- Stephen S. Gottlieb🇺🇸University of Maryland, Baltimore; Veterans Health Administration; Baltimore VA Medical Center
- PRAKASH C. DEEDWANIA🇺🇸University of California, San Francisco; Veterans Health Administration
- Hans Joseph Moore🇺🇸Uniformed Services University of the Health Sciences; Georgetown University; George Washington University; Veterans Health Administration
- Yijun Shao🇺🇸George Washington University; Veterans Health Administration
- Helen M. Sheriff🇺🇸George Washington University; Veterans Health Administration
- Wen‐Chih Wu🇺🇸Brown University; Providence VA Medical Center
- Qing Zeng‐Treitler🇺🇸George Washington University; Veterans Health Administration
- Ali Ahmed🇺🇸 · autor de correspondenciaGeorgetown University; George Washington University; Veterans Health Administration
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
Magnesium deficiency is associated with poor outcomes in patients with heart failure (HF), but less is known about the impact of oral magnesium therapy. This study aimed to examine the association of oral magnesium with outcomes in patients with HF and whether it depends on baseline serum magnesium.
Methods
Of 54 696 Veterans with HF (2001-2023) and hypomagnesemia (serum magnesium <1.7 mg/dL), 10 695 were initiated on oral magnesium (median dose, 420 mg/day). A propensity score-matched cohort of 21 098 patients (treated, n = 10 549) balanced on 71 baseline characteristics was assembled while remaining outcome-blinded. This process was repeated to assemble a matched cohort of 11 634 patients (treated, n = 5817) with normomagnesemia (serum magnesium, 1.7-2.3 mg/dL). Hazard ratios (HR) (95% confidence intervals [CIs]) for one-year outcomes associated with oral magnesium were estimated.
Results
In the hypomagnesemia cohort, HF hospitalization or death occurred in 21.7% of patients not receiving and 20.1% receiving oral magnesium (HR: 0.91; 95% CI: 0.86-0.97). Respective HRs (95% CIs) in subgroups with serum magnesium 1.6 (n = 5929), 1.3-1.5 (n = 11 293) and 1.8 mg/dL, and not significant at 1.5-1.8 mg/dL.
Conclusions
Oral magnesium therapy was associated with a lower risk of HF hospitalization or death in patients with HF and hypomagnesemia. Future clinical trials need to confirm these findings.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.